REGENXBIO to Participate in Upcoming Investor Conferences

Rhea-AI Summary

REGENXBIO (Nasdaq: RGNX) announced its participation in two key investor conferences in March 2023. The Barclays Global Healthcare Conference is scheduled for March 15 at 5:00 p.m. ET in Miami, FL, featuring a fireside chat. Additionally, the company will participate in the BMO Biopharma Spotlight Series on March 28 at 9:00 a.m. ET, focusing on novel genetic medicine delivery technologies in a virtual format. Investors can access a live webcast of the Barclays event on the REGENXBIO website, with an archived replay available for 30 days following the presentation.

ROCKVILLE, Md., March 8, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:

Barclays Global Healthcare Conference
Fireside Chat Date: Wednesday, March 15, 2023
Fireside Chat Time: 5:00 p.m. ET
Location: Miami, FL

BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines Panel: Innovative AAVs Targeting Diverse Tissues
Panel Date: Tuesday, March 28, 2023
Panel Time: 9:00 a.m. ET
Location: Virtual

A live webcast of the presentation at the Barclays Global Healthcare Conference can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8 and AAV9. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.

Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301765374.html

SOURCE REGENXBIO Inc.

FAQ

What investor conferences will REGENXBIO participate in March 2023?

REGENXBIO will participate in the Barclays Global Healthcare Conference on March 15, 2023, and the BMO Biopharma Spotlight Series on March 28, 2023.

What is the schedule for the Barclays Global Healthcare Conference for RGNX?

The Barclays Global Healthcare Conference fireside chat for RGNX is scheduled for March 15, 2023, at 5:00 p.m. ET.

Where can I watch the REGENXBIO conference presentations?

You can watch the live webcast of the REGENXBIO presentations on their official website, www.regenxbio.com.

What topics will be discussed at the BMO Biopharma Spotlight Series?

The BMO Biopharma Spotlight Series will focus on innovative AAVs targeting diverse tissues for genetic medicine delivery.

How long will the archived webcast of REGENXBIO's presentations be available?

The archived webcast of REGENXBIO's presentations will be available for approximately 30 days after the live events.